New biomarker test – the fifth QIAGEN oncology test with FDA clearance in the U.S. – designed to aid diagnosis of patients suspected of having Polycythemia Vera form of blood cancer Germantown, Maryland, and Hilden, Germany, March 29, 2017 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. launch of its ipsogen® JAK2 RGQ… Read article →
Since the arrival of personalized healthcare and molecular diagnostics, there has been growing support for utilizing DNA, RNA, and protein-based biomarker detection methods as a means to help reduce rising healthcare costs (1). Molecular diagnostics can help select the right patients for the right treatments, and define which patients require costly confirmatory diagnostic tests. In… Read article →
We’re excited to join @tbcontrollers at the 2018 National TB Conference in Palm Springs, CA to discuss changes in… https://t.co/zGstE5FNa0, Thank you @AMPath and all visitors for a great and insightful event in Rotterdam. We are looking forward to see you… https://t.co/GbVNualoEQ, QIAGEN reports results for first quarter 2018
https://t.co/WzAhoClXyy https://t.co/5FY4StmXeb, QIAGEN CEO Peer Schatz talked with us at #AMPeurope2018 about the importance of the conference, engaging with inter… https://t.co/5Ve12ahISy, Learn more about the first complete Sample to Insight #NGS solution designed for any research lab to deliver action… https://t.co/pPTXSQymv7, 